Galapagos - GLPG Stock Forecast, Price & News

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galapagos in the last twelve months. There are currently 7 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" GLPG shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GLPG, but not buy additional shares or sell existing shares.
View GLPG analyst ratings or view top-rated stocks.

7 Wall Street research analysts have issued 12 month price targets for Galapagos' stock. Their GLPG share price forecasts range from $40.00 to $70.00. On average, they expect the company's stock price to reach $52.46 in the next twelve months. This suggests a possible upside of 21.1% from the stock's current price.
View analysts price targets for GLPG or view top-rated stocks among Wall Street analysts.

Galapagos' stock was trading at $44.38 at the beginning of the year. Since then, GLPG shares have decreased by 2.4% and is now trading at $43.33.
View the best growth stocks for 2023 here.

Galapagos saw a decrease in short interest during the month of January. As of January 15th, there was short interest totaling 1,010,000 shares, a decrease of 12.9% from the December 31st total of 1,160,000 shares. Based on an average daily volume of 174,300 shares, the short-interest ratio is currently 5.8 days.
View Galapagos' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our GLPG earnings forecast.

6 employees have rated Galapagos Chief Executive Officer Onno van de Stolpe on Glassdoor.com. Onno van de Stolpe has an approval rating of 100% among the company's employees. This puts Onno van de Stolpe in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Galapagos investors own include Gilead Sciences (GILD), Celyad Oncology (CYAD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), argenx (ARGX), AbbVie (ABBV), Biogen (BIIB), Pharming Group (PHGUF), Trade Desk (TTD) and Collegium Pharmaceutical (COLL).

(GLPG) raised $161 million in an initial public offering (IPO) on Thursday, May 14th 2015. The company issued 3,800,000 shares at a price of $42.43 per share. Morgan Stanley, Credit Suisse and Cowen and Company acted as the underwriters for the IPO and Nomura and Bryan, Garnier were co-managers.

Galapagos trades on the NASDAQ under the ticker symbol "GLPG."

Galapagos' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Monaco Asset Management SAM (0.03%), XR Securities LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%).

Shares of GLPG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GLPG stock can currently be purchased for approximately $43.33.

Galapagos (NASDAQ:GLPG) has a market capitalization of $2.85 billion and generates $573.66 million in revenue each year.

The company employs 1,309 workers across the globe.

Galapagos' mailing address is GEN DE WITTELAAN L11 A3, MECHELEN C9, 2800. The official website for the company is www.glpg.com. The biotechnology company can be reached via phone at (321) 534-2900, via email at ir@glpg.com, or via fax at 321-534-2901.